The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

Drug industry calls out telehealth company Hims & Hers' Super Bowl ad touting its knock-off weight loss medications.

Hims & Hers wants to keep on selling a compounded version of Ozempic. And it's channeling anti-establishment vibes to make its case.

Novo Nordisk sells the drug under the brand names Wegovy to treat obesity and heart disease and Ozempic to treat Type 2 diabetes. Compounding pharmacies are regulated by state boards of pharmacy ...

The ad violates federal rules requiring “that advertising for prescription drugs – including compounded drugs – not be false ...

CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...

We talk about them below, but examples include: Off-label marketing risk ... in January 2025, Novo Nordisk’s semaglutide-based GLP-1 drugs (including Ozempic and Wegovy) were listed among ...

Two healthcare stocks in the white-hot weight-loss segment tanked on Monday as one of their rivals zoomed higher. The ...

Novo Nordisk A/S shares are on track for their worst week this year, after a Super Bowl advertisement touting copycat ...

This includes ethical business practices, fair competition, and responsible marketing ... Internationally, Novo Nordisk A/S (NYSE:NVO) is launching Wegovy in more than 15 countries and is ...